| Year |
Citation |
Score |
| 2020 |
Abrams ST, Su D, Sahraoui Y, Lin Z, Cheng Z, Nesbitt K, Alhamdi Y, Harrasser M, Du M, Foley J, Lillicrap D, Wang G, Toh CH. Assembly of alternative prothrombinase by extracellular histones initiate and disseminate intravascular coagulation. Blood. PMID 32722805 DOI: 10.1182/Blood.2019002973 |
0.321 |
|
| 2020 |
Zakas PM, Healey JF, Smith IW, Lillicrap D, Lollar P. Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII. Frontiers in Immunology. 11: 150. PMID 32117290 DOI: 10.3389/Fimmu.2020.00150 |
0.324 |
|
| 2020 |
Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. British Journal of Haematology. PMID 32064603 DOI: 10.1111/Bjh.16377 |
0.326 |
|
| 2020 |
Jae Choi S, Lillicrap D. A sticky proposition: The endothelial glycocalyx and von Willebrand factor. Journal of Thrombosis and Haemostasis : Jth. PMID 31984614 DOI: 10.1111/Jth.14743 |
0.307 |
|
| 2019 |
Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating Factor VIII: Recent Progress. Frontiers in Immunology. 10: 2991. PMID 31998296 DOI: 10.3389/Fimmu.2019.02991 |
0.342 |
|
| 2019 |
Ghorbanpour E, Lillicrap D. Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis. Seminars in Thrombosis and Hemostasis. PMID 31404933 DOI: 10.1055/S-0039-1692977 |
0.31 |
|
| 2019 |
Swystun LL, Ogiwara K, Rawley O, Brown C, Georgescu I, Hopman W, Labarque V, Male C, Thom K, Blanchette VS, Carcao M, Lillicrap D. Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. Blood. PMID 31350267 DOI: 10.1182/Blood.2019000190 |
0.348 |
|
| 2019 |
Batty P, Lillicrap D. Advances and Challenges for Hemophilia Gene Therapy. Human Molecular Genetics. PMID 31332444 DOI: 10.1093/Hmg/Ddz157 |
0.349 |
|
| 2019 |
Swystun LL, Ogiwara K, Lai JD, Ojala JRM, Rawley O, Lassalle F, Notley C, Rengby O, Michels A, Nesbitt K, Tryggvason K, Lillicrap D. The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen. Journal of Thrombosis and Haemostasis : Jth. PMID 31126000 DOI: 10.1111/Jth.14521 |
0.352 |
|
| 2019 |
Swystun LL, Notley C, Georgescu I, Lai JD, Nesbitt K, James PD, Lillicrap D. The endothelial lectin clearance receptor CLEC4M binds and internalizes Factor VIII in a VWF-dependent and -independent manner. Journal of Thrombosis and Haemostasis : Jth. PMID 30740857 DOI: 10.1111/Jth.14404 |
0.347 |
|
| 2019 |
Nava T, Dubé E, Gauthier J, Vézina C, Bonnefoy A, Lillicrap D, Rivard GE. Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes. Haemophilia : the Official Journal of the World Federation of Hemophilia. PMID 30690834 DOI: 10.1111/Hae.13686 |
0.323 |
|
| 2018 |
Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. Journal of Thrombosis and Haemostasis : Jth. PMID 30246494 DOI: 10.1111/Jth.14304 |
0.344 |
|
| 2018 |
Swystun LL, Lai JD, Notley C, Georgescu I, Paine AS, Mewburn J, Nesbitt K, Schledzewski K, Géraud C, Kzhyshkowska J, Goerdt S, Hopman W, Montgomery RR, James PD, Lillicrap D. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. The Journal of Clinical Investigation. PMID 30124466 DOI: 10.1172/Jci96400 |
0.375 |
|
| 2018 |
Lai JD, Swystun LL, Cartier D, Nesbitt K, Zhang C, Hough C, Dennis JW, Lillicrap D. N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice. Haematologica. PMID 30002126 DOI: 10.3324/Haematol.2018.188219 |
0.375 |
|
| 2018 |
Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC, Lillicrap D, Hampshire DJ. The common single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Advances. 2: 1585-1594. PMID 29980574 DOI: 10.1182/Bloodadvances.2017011643 |
0.368 |
|
| 2018 |
Georgescu MT, Moorehead PC, van Velzen AS, Nesbitt K, Reipert BM, Steinitz KN, Schuster M, Hough C, Lillicrap D. Dexamethasone promotes durable factor VIII -specific tolerance in hemophilia A mice via thymic mechanisms. Haematologica. PMID 29674503 DOI: 10.3324/Haematol.2018.189852 |
0.349 |
|
| 2018 |
Blumberg RS, Lillicrap D. Tolerogenic properties of Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. PMID 29588277 DOI: 10.1182/Blood-2017-12-822908 |
0.343 |
|
| 2017 |
Lillicrap D. FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B. Cell. 171: 1478-1480. PMID 29245009 DOI: 10.1016/J.Cell.2017.11.049 |
0.338 |
|
| 2017 |
Michels A, Swystun LL, Mewburn J, Albánez S, Lillicrap D. Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation. Journal of Visualized Experiments : Jove. PMID 28829426 DOI: 10.3791/55917 |
0.327 |
|
| 2017 |
Lillicrap D. Thrombolytic Potential of N-Acetylcysteine: Evidence for Significant Benefit in Mitigating Arterial Thrombosis. Circulation. 136: 661-663. PMID 28808146 DOI: 10.1161/Circulationaha.117.029313 |
0.314 |
|
| 2017 |
Lillicrap D. Bispecific Antibody Therapy in Hemophilia. The New England Journal of Medicine. PMID 28691560 DOI: 10.1056/Nejme1707802 |
0.377 |
|
| 2017 |
Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D. Abnormal von Willebrand factor secretion, factor VIII stabilization, and thrombus dynamics in type 2N von Willebrand disease mice. Journal of Thrombosis and Haemostasis : Jth. PMID 28581694 DOI: 10.1111/Jth.13749 |
0.383 |
|
| 2017 |
Bowman ML, Pluthero FG, Tuttle A, Casey L, Li L, Christensen H, Robinson KS, Lillicrap D, Kahr WHA, James P. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24. Journal of Thrombosis and Haemostasis : Jth. PMID 28453889 DOI: 10.1111/Jth.13722 |
0.372 |
|
| 2017 |
Lai JD, Lillicrap D. Factor VIII inhibitors: Advances in basic and translational science. International Journal of Laboratory Hematology. 39: 6-13. PMID 28447409 DOI: 10.1111/Ijlh.12659 |
0.318 |
|
| 2017 |
Lai J, Hough C, Tarrant J, Lillicrap D. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. PMID 28432221 DOI: 10.1182/Blood-2016-11-750885 |
0.358 |
|
| 2017 |
Labarque V, Perinparajah V, Bouskill V, Marie Stain A, Wakefield C, Manuel C, Blanchette VS, James PD, Lillicrap D, Carcao MD. Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A. American Journal of Hematology. PMID 28249352 DOI: 10.1002/Ajh.24709 |
0.335 |
|
| 2017 |
Desch K, Ozel AB, Halvorsen M, Michels AL, Swystun LL, Mokry L, Richards B, Germain M, Tregouet DA, Reitsma PH, Kearon C, Li JZ, Goldstein DB, Lillicrap D, Ginsburg D. Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease Blood. 130: 457-457. DOI: 10.1182/Blood.V130.Suppl_1.457.457 |
0.404 |
|
| 2017 |
Solecka-Witulska BA, Lillicrap D, Hough C, Kannicht C. A Novel Von Willebrand Factor Fragment Acts As a Chaperone to Prolong the Half-Life of Recombinant Human FVIII (Simoctocog Alfa) in Hemophilia a Dogs and FVIII/VWF Double Knockout Mice Blood. 130: 178-178. DOI: 10.1182/Blood.V130.Suppl_1.178.178 |
0.319 |
|
| 2016 |
Michels A, Albánez S, Mewburn J, Nesbitt K, Gould TJ, Liaw PC, James PD, Swystun LL, Lillicrap D. Histones link inflammation and thrombosis through the induction of Weibel-Palade Body exocytosis. Journal of Thrombosis and Haemostasis : Jth. PMID 27589692 DOI: 10.1111/Jth.13493 |
0.316 |
|
| 2016 |
Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. PMID 27587878 DOI: 10.1182/Blood-2016-04-713289 |
0.331 |
|
| 2016 |
Swystun LL, Lillicrap D. How much do we really know about von Willebrand disease? Current Opinion in Hematology. PMID 27428891 DOI: 10.1097/Moh.0000000000000272 |
0.302 |
|
| 2016 |
Shima M, Lillicrap D, Kruse-Jarres R. Alternative therapies for the management of inhibitors. Haemophilia : the Official Journal of the World Federation of Hemophilia. 22: 36-41. PMID 27405674 DOI: 10.1111/Hae.13005 |
0.345 |
|
| 2016 |
Swystun LL, Lillicrap D. Gene Therapy for Coagulation Disorders. Circulation Research. 118: 1443-52. PMID 27126652 DOI: 10.1161/Circresaha.115.307015 |
0.345 |
|
| 2016 |
Albánez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, Lillicrap D. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. Journal of Thrombosis and Haemostasis : Jth. 14: 953-63. PMID 26875505 DOI: 10.1111/Jth.13294 |
0.328 |
|
| 2016 |
Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, ... ... Lillicrap D, et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. PMID 26862110 DOI: 10.1182/Blood-2015-10-673681 |
0.306 |
|
| 2016 |
Lai J, Swystun LL, Cartier D, Zhang C, Nesbitt K, Dennis J, Hough C, Lillicrap D. Differential Glycosylation Between Recombinant Factor VIII Produced in Baby Hamster Kidney and Chinese Hamster Ovary Cells Confers Differences in Immunogenicity in a Humanized Hemophilia Α Mouse Model Blood. 128: 326-326. DOI: 10.1182/Blood.V128.22.326.326 |
0.346 |
|
| 2016 |
Swystun LL, Dwyer C, Nesbitt K, Hebert K, Lillicrap D. VWF-FVIII Interactions Influence Hemostatic Thrombus Stability in Murine Models of Hemophilia Α and Type 2N VWD Blood. 128: 1403-1403. DOI: 10.1182/Blood.V128.22.1403.1403 |
0.318 |
|
| 2016 |
Riley BE, Boonsripisal J, Goodwin A, Cartier D, Garces E, Nesbitt K, Dwyer C, Ballaron S, Hebert K, Tran H, Kang A, Zhang L, Meyer KE, Greengard J, Hough C, ... ... Lillicrap D, et al. Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy Blood. 128: 1173-1173. DOI: 10.1182/Blood.V128.22.1173.1173 |
0.341 |
|
| 2016 |
Nichols TC, Hough C, Agersø H, Ezban M, Lillicrap D. Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies Journal of Thrombosis and Haemostasis. DOI: 10.1111/Jth.13301 |
0.331 |
|
| 2015 |
Krishnamoorthy S, Liu T, Drager D, Patarroyo-White S, Chhabra ES, Peters R, Josephson N, Lillicrap D, Blumberg RS, Pierce GF, Jiang H. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cellular Immunology. PMID 26775174 DOI: 10.1016/J.Cellimm.2015.12.008 |
0.333 |
|
| 2015 |
Crawford B, Ozelo MC, Ogiwara K, Ahlin J, Albanez S, Hegadorn C, Harpell L, Hough C, Lillicrap D. Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII. Molecular Therapy. Methods & Clinical Development. 2: 15033. PMID 26636112 DOI: 10.1038/Mtm.2015.33 |
0.302 |
|
| 2015 |
Lai JD, Georgescu MT, Hough C, Lillicrap D. To clear or to fear: An innate perspective on factor VIII immunity. Cellular Immunology. PMID 26547364 DOI: 10.1016/J.Cellimm.2015.10.011 |
0.325 |
|
| 2015 |
Lillicrap D, Schiviz A, Apostol C, Wojciechowski P, Horling F, Lai CK, Piskernik C, Hoellriegl W, Lollar P. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia : the Official Journal of the World Federation of Hemophilia. PMID 26278557 DOI: 10.1111/Hae.12784 |
0.323 |
|
| 2015 |
Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia : the Official Journal of the World Federation of Hemophilia. 21: 636-41. PMID 25756206 DOI: 10.1111/Hae.12664 |
0.309 |
|
| 2015 |
Oldenburg J, Lacroix-Desmazes S, Lillicrap D. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica. 100: 149-56. PMID 25638804 DOI: 10.3324/Haematol.2014.112821 |
0.369 |
|
| 2015 |
Moorehead PC, Thibeault L, Tuttle A, Grabell J, Dwyre L, Silva M, James P, Lillicrap D. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor. Journal of Pediatric Hematology/Oncology. 37: e220-2. PMID 25411864 DOI: 10.1097/Mph.0000000000000287 |
0.301 |
|
| 2014 |
Lillicrap D. Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets. The Journal of Clinical Investigation. 124: 4231-3. PMID 25244090 DOI: 10.1172/Jci77511 |
0.365 |
|
| 2014 |
Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of Thrombosis and Haemostasis : Jth. 12: 1788-800. PMID 25196897 DOI: 10.1111/Jth.12723 |
0.318 |
|
| 2014 |
Shida Y, Rydz N, Stegner D, Brown C, Mewburn J, Sponagle K, Danisment O, Crawford B, Vidal B, Hegadorn CA, Pruss CM, Nieswandt B, Lillicrap D. Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation. Blood. 124: 1799-807. PMID 25051961 DOI: 10.1182/Blood-2013-09-521484 |
0.363 |
|
| 2014 |
Swystun LL, Lillicrap D. FVIII stabilization: VWF D'D3 will do. Blood. 124: 313-5. PMID 25035147 DOI: 10.1182/Blood-2014-06-578955 |
0.343 |
|
| 2014 |
Ozelo MC, Vidal B, Brown C, Notley C, Hegadorn C, Webster S, Harpell L, Ahlin J, Winterborn A, Handforth J, Arruda VR, Hough C, Lillicrap D. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood. 123: 4045-53. PMID 24829206 DOI: 10.1182/Blood-2013-12-545780 |
0.343 |
|
| 2014 |
Lillicrap D, Fijnvandraat K, Santagostino E. Inhibitors - genetic and environmental factors. Haemophilia. 20: 87-93. PMID 24762282 DOI: 10.1111/Hae.12412 |
0.342 |
|
| 2014 |
High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia : the Official Journal of the World Federation of Hemophilia. 20: 43-9. PMID 24762274 DOI: 10.1111/Hae.12411 |
0.336 |
|
| 2014 |
Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M, O'Donnell J, Pipe S, Santagostino E, Saint-Remy JM, Schramm W, Iorio A. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia : the Official Journal of the World Federation of Hemophilia. 20: 200-6. PMID 24533949 DOI: 10.1111/Hae.12283 |
0.319 |
|
| 2014 |
Ogiwara K, Swystun LL, Georgescu I, Brown C, Tuttle A, Tinlin S, Leggo J, Albánez S, Carcao M, Blanchette VS, Male C, Thom K, Lillicrap D. Clearance and Genetic Variability of Von Willebrand Factor Are Major Determinants of the Pharmacokinetic Behavior of Factor VIII Concentrates in the Treatment of Pediatric Hemophilia A Blood. 124: 473-473. DOI: 10.1182/Blood.V124.21.473.473 |
0.395 |
|
| 2014 |
Swystun LL, Georgescu I, Deforest M, Golder M, Sponagle K, Brown C, Notley C, Lillicrap D. Characterization of Type 2N Von Willebrand Disease Mutations Using Ιn Vitro and Ιn Vivo Mouse Models Blood. 124: 471-471. DOI: 10.1182/Blood.V124.21.471.471 |
0.351 |
|
| 2014 |
Albánez S, Michels A, Sponagle K, Lillicrap D. Age-Related Increases in Plasma Factor VIII and Von Willebrand Factor in a C57BL/6 Mouse Model Are Associated with Increased Factor VIII and Von Willebrand Factor Gene Expression and Reduced Expression of the Clearance Receptor, Stabilin-2 Blood. 124: 4228-4228. DOI: 10.1182/Blood.V124.21.4228.4228 |
0.359 |
|
| 2014 |
Albánez S, Ogiwara K, Grabell J, James P, Lillicrap D. C0323: Age-Related Changes to the Mechanisms Responsible for Regulating Plasma Levels of Von Willebrand Factor and Factor VIII Thrombosis Research. 133. DOI: 10.1016/S0049-3848(14)50114-4 |
0.341 |
|
| 2013 |
Tatsumi K, Sugimoto M, Lillicrap D, Shima M, Ohashi K, Okano T, Matsui H. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A. Plos One. 8: e83280. PMID 24358271 DOI: 10.1371/Journal.Pone.0083280 |
0.325 |
|
| 2013 |
Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013: 254-60. PMID 24319188 DOI: 10.1182/Asheducation-2013.1.254 |
0.405 |
|
| 2013 |
Peyvandi F, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. Blood. 122: 3423-31. PMID 24124085 DOI: 10.1182/Blood-2013-05-505511 |
0.355 |
|
| 2013 |
Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 122: 3735-40. PMID 24065240 DOI: 10.1182/Blood-2013-06-498303 |
0.405 |
|
| 2013 |
Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, et al. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nature Medicine. 19: 1318-24. PMID 24037092 DOI: 10.1038/Nm.3270 |
0.318 |
|
| 2013 |
Rydz N, Natalia R, Leggo J, Jayne L, Tinlin S, Shawn T, James P, Paula J, Lillicrap D, David L. The Canadian "National Program for hemophilia mutation testing" database: a ten-year review. American Journal of Hematology. 88: 1030-4. PMID 23913812 DOI: 10.1002/Ajh.23557 |
0.33 |
|
| 2013 |
Bowman M, Lillicrap D, James P. The genetics of Canadian type 3 von Willebrand disease: further evidence for codominant inheritance of mutant alleles: a reply to a rebuttal. Journal of Thrombosis and Haemostasis : Jth. 11: 1786-7. PMID 23844668 DOI: 10.1111/Jth.12348 |
0.325 |
|
| 2013 |
Lillicrap D. Translational medicine advances in von Willebrand disease. Journal of Thrombosis and Haemostasis. 11: 75-83. PMID 23809112 DOI: 10.1111/Jth.12257 |
0.327 |
|
| 2013 |
Kahlon A, Grabell J, Tuttle A, Engen D, Hopman W, Lillicrap D, James P. Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals. Haemophilia : the Official Journal of the World Federation of Hemophilia. 19: 758-64. PMID 23711418 DOI: 10.1111/Hae.12185 |
0.316 |
|
| 2013 |
Rydz N, Swystun LL, Notley C, Paterson AD, Riches JJ, Sponagle K, Boonyawat B, Montgomery RR, James PD, Lillicrap D. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 121: 5228-37. PMID 23529928 DOI: 10.1182/Blood-2012-10-457507 |
0.385 |
|
| 2013 |
James PD, Lillicrap D. The molecular characterization of von Willebrand disease: good in parts British Journal of Haematology. 161: 166-176. PMID 23406206 DOI: 10.1111/Bjh.12249 |
0.336 |
|
| 2013 |
Berntorp E, Fuchs B, Makris M, Montgomery R, Flood V, O'Donnell JS, Federici AB, Lillicrap D, James P, Budde U, Morfini M, Petrini P, Austin S, Kannicht C, Jiménez-Yuste V, et al. Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. Haemophilia : the Official Journal of the World Federation of Hemophilia. 1-18. PMID 23383607 DOI: 10.1111/Hae.12078 |
0.334 |
|
| 2013 |
Bowman M, Tuttle A, Notley C, Brown C, Tinlin S, Deforest M, Leggo J, Blanchette VS, Lillicrap D, James P. The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles. Journal of Thrombosis and Haemostasis : Jth. 11: 512-20. PMID 23311757 DOI: 10.1111/Jth.12130 |
0.364 |
|
| 2013 |
James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 122: 636-40. PMID 23297130 DOI: 10.1182/Blood-2012-10-462085 |
0.356 |
|
| 2013 |
Golder M, Mewburn J, Lillicrap D. In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process. Thrombosis and Haemostasis. 109: 53-60. PMID 23178924 DOI: 10.1160/Th12-05-0316 |
0.309 |
|
| 2013 |
Swystun LL, Brown C, Mewburn J, Sponagle K, Danisment O, Riches J, Hough C, Lillicrap D. Platelet-Mediated Mechanical Tensile Force Influences ADAMTS13 Localization and Regulation Of Thrombus Development At The Site Of Platelet Accumulation Blood. 122: 454-454. DOI: 10.1182/Blood.V122.21.454.454 |
0.351 |
|
| 2013 |
Snetsinger B, Lin C, Weng W, Cull A, Sponagle K, Hough C, Lillicrap D. Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications Blood. 122: 3569-3569. DOI: 10.1182/Blood.V122.21.3569.3569 |
0.304 |
|
| 2013 |
Christopherson P, Bellissimo DB, Gill JC, Haberichter SL, Flood VH, Lillicrap D, Goodeve AC, Friedman KD, Abshire TC, Shapiro AD, Ragni MV, Lentz SR, Leissinger CA, Dunn AL, Lusher J, et al. The Complete Type I VWD Cohort Of The Zimmerman Program For The Molecular and Clinical Biology Of VWD - Phenotypic Assignment, Mutation Frequency, and Bleeding Assessment Blood. 122: 332-332. DOI: 10.1182/Blood.V122.21.332.332 |
0.327 |
|
| 2013 |
Notley C, Sponagle K, James PD, Lillicrap D. Regulation Of Factor VIII Clearance By Mannose-Binding Lectins Blood. 122: 2340-2340. DOI: 10.1182/Blood.V122.21.2340.2340 |
0.371 |
|
| 2013 |
Swystun LL, Notley C, Georgescu I, James PD, Lillicrap D. The Endothelial Lectin Receptor CLEC4M Internalizes Factor VIII and Von Willebrand Factor Via a Clathrin-Coated Pit-Dependent Mechanism Blood. 122: 1091-1091. DOI: 10.1182/Blood.V122.21.1091.1091 |
0.33 |
|
| 2012 |
Lillicrap D. A complex substitute: antibody therapy for hemophilia. Nature Medicine. 18: 1460-1. PMID 23042345 DOI: 10.1038/Nm.2959 |
0.313 |
|
| 2012 |
James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. American Journal of Hematology. 87: S4-11. PMID 22389132 DOI: 10.1002/Ajh.23142 |
0.343 |
|
| 2012 |
Pruss CM, Golder M, Bryant A, Hegadorn C, Haberichter S, Lillicrap D. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. Journal of Thrombosis and Haemostasis : Jth. 10: 940-50. PMID 22372972 DOI: 10.1111/J.1538-7836.2012.04675.X |
0.379 |
|
| 2012 |
Foley JH, Petersen KU, Rea CJ, Harpell L, Powell S, Lillicrap D, Nesheim ME, Sørensen B. Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood. 119: 3622-8. PMID 22234684 DOI: 10.1182/Blood-2011-11-392308 |
0.327 |
|
| 2012 |
Berber E, Brown C, Incekara K, Baslar Z, Caglayan H, Lillicrap D. Functional characterization of the type 1 VWD candidate VWF gene variants: P.M771I, p.L881R, p.P1413L, and p.Q1475X Blood. 120: 97-97. DOI: 10.1182/Blood.V120.21.97.97 |
0.343 |
|
| 2012 |
Swystun LL, Rydz N, Notley C, Riches JJ, Paterson AD, Montgomery RR, James PD, Lillicrap D. Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels Blood. 120: 16-16. DOI: 10.1182/Blood.V120.21.16.16 |
0.408 |
|
| 2012 |
Walker I, Traore AN, Iorio A, Ritchie B, Heddle N, Webert KE, St. Louis J, Lillicrap D, Teitel JM, Chan AK. Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends Blood. 120: 1186-1186. DOI: 10.1182/Blood.V120.21.1186.1186 |
0.314 |
|
| 2011 |
Pruss CM, Golder M, Bryant A, Hegadorn CA, Burnett E, Laverty K, Sponagle K, Dhala A, Notley C, Haberichter S, Lillicrap D. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood. 117: 4358-66. PMID 21346256 DOI: 10.1182/Blood-2010-08-303727 |
0.356 |
|
| 2011 |
Hamilton A, Ozelo M, Leggo J, Notley C, Brown H, Frontroth JP, Angelillo-Scherrer A, Baghaei F, Enayat SM, Favaloro E, Lillicrap D, Othman M. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thrombosis and Haemostasis. 105: 501-8. PMID 21301777 DOI: 10.1160/Th10-08-0523 |
0.372 |
|
| 2011 |
Matsui H, Hegadorn C, Ozelo M, Burnett E, Tuttle A, Labelle A, McCray PB, Naldini L, Brown B, Hough C, Lillicrap D. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 723-30. PMID 21285959 DOI: 10.1038/Mt.2010.290 |
0.323 |
|
| 2011 |
Chegeni R, Vickars L, Favaloro EJ, Lillicrap D, Othman M. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease. Thrombosis Research. 127: 161-6. PMID 21094983 DOI: 10.1016/J.Thromres.2010.11.006 |
0.399 |
|
| 2011 |
Coutu DL, Cuerquis J, El Ayoubi R, Forner KA, Roy R, François M, Griffith M, Lillicrap D, Yousefi AM, Blostein MD, Galipeau J. Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B. Biomaterials. 32: 295-305. PMID 20864158 DOI: 10.1016/J.Biomaterials.2010.08.094 |
0.312 |
|
| 2011 |
Shida Y, Brown C, Mewburn J, Sponagle K, Danisment O, Vidal B, Heagadorn CA, Lillicrap D. Comprehensive In Vitro and In Vivo Characterization of Loss and Gain-of-Function Von Willebrand Factor Collagen Binding Variants Using a Mouse Model System, Blood. 118: 3266-3266. DOI: 10.1182/Blood.V118.21.3266.3266 |
0.377 |
|
| 2010 |
Finn JD, Ozelo MC, Sabatino DE, Franck HWG, Merricks EP, Crudele JM, Zhou S, Kazazian HH, Lillicrap D, Nichols TC, Arruda VR. Eradication of neutralizing antibodies to factor VIII In canine hemophilia a after liver gene therapy Blood. 116: 5842-5848. PMID 20876851 DOI: 10.1182/Blood-2010-06-288001 |
0.335 |
|
| 2010 |
Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, Buckley S, Waddington S, Parker AL, Baker A, James P, Lillicrap D. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood. 116: 3645-52. PMID 20696945 DOI: 10.1182/Blood-2009-12-261131 |
0.432 |
|
| 2010 |
Othman M, Powell S, Hopman WM, Lillicrap D. Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis Haemophilia. 16: 919-925. PMID 20609015 DOI: 10.1111/J.1365-2516.2010.02336.X |
0.323 |
|
| 2010 |
Reipert B, Arruda V, Lillicrap D. Animal models of inhibitors. Haemophilia. 16: 47-53. PMID 20590856 DOI: 10.1111/J.1365-2516.2010.02293.X |
0.337 |
|
| 2010 |
Golder M, Pruss CM, Hegadorn C, Mewburn J, Laverty K, Sponagle K, Lillicrap D. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions. Blood. 115: 4862-9. PMID 20371742 DOI: 10.1182/Blood-2009-11-253120 |
0.355 |
|
| 2010 |
Lillicrap D. Genetic Characterization of Hemophilia and Implications for Novel Therapies Blood. 116. DOI: 10.1182/Blood.V116.21.Sci-9.Sci-9 |
0.39 |
|
| 2010 |
Golder M, Pruss CM, Sponagle K, Hegadorn C, Burnett E, Bryant A, Lillicrap D. A Modified Model of Type 2B von Willebrand Disease: Taking ADAMTS13-Mediated Cleavage out of the Equation Blood. 116: 23-23. DOI: 10.1182/Blood.V116.21.23.23 |
0.339 |
|
| 2010 |
Hampshire DJ, Bloomer LD, Al-Buhairan AM, Coyle RE, Vijzelaar RNCP, Lillicrap D, James PD, Eikenboom JCJ, Schneppenheim R, Rodeghiero F, Montgomery RR, Peake IR, Goodeve AC. Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease Blood. 116: 2218-2218. DOI: 10.1182/Blood.V116.21.2218.2218 |
0.364 |
|
| 2010 |
Pruss CM, Golder M, Bryant A, Burnett E, Sponagle K, Hegadorn C, Haberichter SL, Lillicrap D. Mouse Models of the Common, Recurring Type 1 von Willebrand Disease Mutations Y1584C and R1205H Blood. 116: 22-22. DOI: 10.1182/Blood.V116.21.22.22 |
0.324 |
|
| 2009 |
Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? Journal of Thrombosis and Haemostasis. 7: 65-70. PMID 19630771 DOI: 10.1111/J.1538-7836.2009.03367.X |
0.386 |
|
| 2009 |
Berber E, James PD, Hough C, Lillicrap D. An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution Journal of Thrombosis and Haemostasis. 7: 1672-1679. PMID 19624459 DOI: 10.1111/J.1538-7836.2009.03551.X |
0.373 |
|
| 2009 |
Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. Journal of Thrombosis and Haemostasis. 7: 1446-1456. PMID 19583822 DOI: 10.1111/J.1538-7836.2009.03538.X |
0.32 |
|
| 2009 |
Mullah-Ali AM, Chan AK, Lillicrap D, Decker K, Seroski W, Moffat K, Walker I, Pai MK. Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A. Haemophilia : the Official Journal of the World Federation of Hemophilia. 15: 1258-61. PMID 19563498 DOI: 10.1111/J.1365-2516.2009.02062.X |
0.369 |
|
| 2009 |
Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Chuah M, VandenDriessche T, Miao CH, Hough C, Lillicrap D. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Blood. 114: 677-85. PMID 19458355 DOI: 10.1182/Blood-2009-03-202267 |
0.323 |
|
| 2009 |
Qadura M, Waters B, Burnett E, Chegeni R, Bradshaw S, Hough C, Othman M, Lillicrap D. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood. 114: 871-80. PMID 19411636 DOI: 10.1182/Blood-2008-09-174649 |
0.346 |
|
| 2009 |
Othman M, Hamilton A, Lillicrap D. Results of a World Wide Survey On the Diagnostic Dilemma Between Type 2B Von Willeband Disease and the PT-VWD. Blood. 114: 4436-4436. DOI: 10.1182/Blood.V114.22.4436.4436 |
0.305 |
|
| 2009 |
Ozelo MC, Matsui H, Hegadorn CA, Harpell L, Powell S, Hulvat JF, Winterborn A, Handforth J, Hough C, Lillicrap D. Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability. Blood. 114: 3578-3578. DOI: 10.1182/Blood.V114.22.3578.3578 |
0.34 |
|
| 2009 |
Kahr WHA, Pluthero FG, Blanchette VS, Robinson KS, Lillicrap D, James PD. Type 3 Von Willebrand Disease: Plasma Versus Platelets. Blood. 114: 3059-3059. DOI: 10.1182/Blood.V114.22.3059.3059 |
0.383 |
|
| 2009 |
Pruss CM, Sponagle K, Laverty K, Hegadorn CA, Chirinian Y, Notley C, Golder M, Lillicrap D. In Vitro and In Vivo Mouse Models of the Type 1 Von Willebrand Disease Mutations Y1584C and R1205H. Blood. 114: 26-26. DOI: 10.1182/Blood.V114.22.26.26 |
0.335 |
|
| 2009 |
Othman M, Chegeni R, Vickars LM, Favaloro EJ, Lillicrap D. Functional Characterization of Three VWF- A1 Domain Mutations Causing Type 2 Von Willebrand Disease. Blood. 114: 1305-1305. DOI: 10.1182/Blood.V114.22.1305.1305 |
0.408 |
|
| 2009 |
Matsui H, Harpell L, Powell S, Rafei M, Galipeau J, Hough C, Lillicrap D. Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A. Blood. 114: 1299-1299. DOI: 10.1182/Blood.V114.22.1299.1299 |
0.314 |
|
| 2009 |
Kahlon A, Grabell J, Tuttle A, Engen D, Hopman W, Lillicrap D, James P. Quantitation of Changes in VWF and FVIII Following Elective Orthopedic Surgery in Normal Individuals. Blood. 114: 1296-1296. DOI: 10.1182/Blood.V114.22.1296.1296 |
0.314 |
|
| 2008 |
Pruss CM, Notley CR, Hegadorn CA, O'Brien LA, Lillicrap D. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. British Journal of Haematology. 143: 552-8. PMID 18986390 DOI: 10.1111/J.1365-2141.2008.07266.X |
0.749 |
|
| 2008 |
Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thrombosis Research. 122: S2-8. PMID 18929522 DOI: 10.1016/S0049-3848(08)70027-6 |
0.33 |
|
| 2008 |
Kamphuisen PW, Lillicrap D. Coagulation factors--molecular attributes and their clinical impact. Thrombosis Research. 122: S1. PMID 18929520 DOI: 10.1016/S0049-3848(08)70026-4 |
0.303 |
|
| 2008 |
Qadura M, Othman M, Waters B, Chegeni R, Walker K, Labelle A, Ozelo M, Hough C, Lillicrap D. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. Journal of Thrombosis and Haemostasis : Jth. 6: 2095-104. PMID 18826393 DOI: 10.1111/J.1538-7836.2008.03165.X |
0.332 |
|
| 2008 |
Collins PW, Cumming AM, Goodeve AC, Lillicrap D. Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia : the Official Journal of the World Federation of Hemophilia. 14: 685-96. PMID 18510569 DOI: 10.1111/J.1365-2516.2008.01757.X |
0.365 |
|
| 2008 |
Bolton-Maggs PHB, Lillicrap D, Goudemand J, Berntorp E. von Willebrand disease update: diagnostic and treatment dilemmas Haemophilia. 14: 56-61. PMID 18510523 DOI: 10.1111/J.1365-2516.2008.01713.X |
0.34 |
|
| 2008 |
Hough C, Cameron CL, Notley CR, Brown C, O'Brien L, Keightley AM, Berber E, Lillicrap D. Influence of a GT repeat element on shear stress responsiveness of the VWF gene promoter. Journal of Thrombosis and Haemostasis : Jth. 6: 1183-90. PMID 18485092 DOI: 10.1111/J.1538-7836.2008.03011.X |
0.746 |
|
| 2008 |
Liu T, Lillicrap D, Zhang X, Labelle A, Powell S, Mei B, Murphy JE, Pierce GF, Jiang H. Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs Blood. 112: 511-511. DOI: 10.1182/Blood.V112.11.511.511 |
0.365 |
|
| 2008 |
Qadura M, Waters B, Burnett E, Chegeni R, Othman M, Lillicrap D. Investigating the Mechanisms Underlying FVIII Antibody Production in Hemophilic Mice Following Recombinant and Plasma-Derived FVIII Infusion Blood. 112: 237-237. DOI: 10.1182/Blood.V112.11.237.237 |
0.326 |
|
| 2008 |
Pruss CM, Hegadorn CA, Labelle A, Burnett E, Golder M, Lillicrap D. Recombinant Protein Infusion and Hydrodynamic Plasmid Delivery Strategies Provide Distinct and Complementary Approaches to the Characterization of Variant Forms of Von Willeband Factor (VWF) in VWF Knockout Mice. Blood. 112: 2020-2020. DOI: 10.1182/Blood.V112.11.2020.2020 |
0.421 |
|
| 2007 |
Lillicrap D. Von Willebrand disease - phenotype versus genotype: deficiency versus disease. Thrombosis Research. 120: S11-6. PMID 17490730 DOI: 10.1016/J.Thromres.2007.03.014 |
0.403 |
|
| 2007 |
Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment Journal of Thrombosis and Haemostasis. 5: 901-906. PMID 17459005 DOI: 10.1111/J.1538-7836.2007.02410.X |
0.342 |
|
| 2007 |
Barnes C, Blanchette V, Lillicrap D, Mann K, Stain AM, Leggo J, Hilliard P, Carcao M. Different clinical phenotype in triplets with haemophilia A Haemophilia. 13: 202-205. PMID 17286775 DOI: 10.1111/J.1365-2516.2006.01396.X |
0.358 |
|
| 2007 |
James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, ... Lillicrap D, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood. 109: 145-54. PMID 17190853 DOI: 10.1182/Blood-2006-05-021105 |
0.756 |
|
| 2007 |
Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood. 109: 2832-9. PMID 17148587 DOI: 10.1182/Blood-2006-06-032524 |
0.322 |
|
| 2007 |
Flood VH, Kautza BC, Miller CA, Branchford BR, Gill JC, Haberichter SL, Morateck PA, Christopherson PA, Perry CL, Friedman KD, Bellissimo DB, Abshire TC, Paola JAD, Hoots WK, Leissinger C, ... ... Lillicrap D, et al. Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing. Blood. 110: 714-714. DOI: 10.1182/Blood.V110.11.714.714 |
0.34 |
|
| 2007 |
Golder M, Burnett E, Mewburn J, Lillicrap D. Increased Factor VIII Levels Have a Thrombogenic Effect In Vitro and In Vivo. Blood. 110: 3623-3623. DOI: 10.1182/Blood.V110.11.3623.3623 |
0.331 |
|
| 2007 |
Pruss CM, Hegadorn CA, Notley CR, Chegeni R, Dhala AS, Lillicrap D. Human von Willebrand Disease Mutations in Mouse von Willebrand Factor Alter Its Cleavage by ADAMTS13. Blood. 110: 2708-2708. DOI: 10.1182/Blood.V110.11.2708.2708 |
0.392 |
|
| 2007 |
Matsui H, Ozelo M, Hegadorn C, Labelle A, Burnett E, Tuttle A, Brown B, Naldini L, Hough C, Lillicrap D. Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors. Blood. 110: 2587-2587. DOI: 10.1182/Blood.V110.11.2587.2587 |
0.336 |
|
| 2007 |
Lillicrap D. Inducing Tregs with hepatic gene therapy Blood. 110: 1089-1089. DOI: 10.1182/Blood-2007-05-087718 |
0.302 |
|
| 2007 |
Hampshire DJ, James PD, Lillicrap D, Peake IR, Goodeve AC. The Isth Ssc Von Willebrand Factor (Vwf) Online Database Journal of Thrombosis and Haemostasis. 5. DOI: 10.1111/J.1538-7836.2007.Tb01964.X |
0.321 |
|
| 2006 |
Lillicrap D. The role of immunomodulation in the management of factor VIII inhibitors. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 421-5. PMID 17124093 DOI: 10.1182/Asheducation-2006.1.421 |
0.324 |
|
| 2006 |
Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor Journal of Thrombosis and Haemostasis. 4: 2103-2114. PMID 16889557 DOI: 10.1111/J.1538-7836.2006.02146.X |
0.373 |
|
| 2006 |
Berber E, Leggo J, Brown C, Gallo N, Feilotter H, Lillicrap D. DNA microarray analysis for the detection of mutations in hemophilia A. Journal of Thrombosis and Haemostasis. 4: 1756-1762. PMID 16879218 DOI: 10.1111/J.1538-7836.2006.02055.X |
0.315 |
|
| 2006 |
Lee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Seminars in Thrombosis and Hemostasis. 32: 10-4. PMID 16804830 DOI: 10.1055/S-2006-946909 |
0.371 |
|
| 2006 |
James PD, Paterson AD, Notley C, Cameron C, Hegadorn C, Tinlin S, Brown C, O'Brien L, Leggo J, Lillicrap D. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. Journal of Thrombosis and Haemostasis : Jth. 4: 783-92. PMID 16634747 DOI: 10.1111/J.1538-7836.2006.01860.X |
0.731 |
|
| 2006 |
Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, Powell S, Keller T, McMurray M, Labelle A, Nagy D, Vargas JA, Zhou S, Couto LB, Pierce GF. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 108: 107-15. PMID 16522813 DOI: 10.1182/Blood-2005-12-5115 |
0.342 |
|
| 2006 |
Coutu DL, Francois M, Cuerquis J, Matsui H, Lillicrap D, Galipeau J. Ex Vivo Gene Therapy for Haemophilia A: FVIII-Overexpressing Mesenchymal Stromal Cells Fail To Produce Sustained Therapeutic Levels of Circulating FVIII In Vivo. Blood. 108: 5472-5472. DOI: 10.1182/Blood.V108.11.5472.5472 |
0.343 |
|
| 2006 |
Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D. Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors. Blood. 108: 3251-3251. DOI: 10.1182/Blood.V108.11.3251.3251 |
0.357 |
|
| 2006 |
Barnes C, Lillicrap D, Pazmino-Canizares J, Blanchette VS, Stain AM, Clark D, Hensmen C, Carcao M. Pharmacokinetics of recombinant factor VIII (Kogenate-FS®) in children and causes of inter-patient pharmacokinetic variability Haemophilia. 12: 40-49. DOI: 10.1111/J.1365-2516.2006.01333.X |
0.314 |
|
| 2006 |
Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Chuah M, VandenDriessche T, Miao CH, Hough C, Lillicrap D. 1091. Successful Induction of Immune Tolerance to Canine Factor VIII after Lentiviral-Mediated Gene Therapy in Neonatal Hemophilia A Mice Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.1193 |
0.324 |
|
| 2005 |
James PD, Raut S, Rivard GE, Poon MC, Warner M, McKenna S, Leggo J, Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood. 106: 3043-8. PMID 16051741 DOI: 10.1182/Blood-2005-03-1307 |
0.328 |
|
| 2005 |
O'Brien LA, Sutherland JJ, Weaver DF, Lillicrap D. Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. Journal of Thrombosis and Haemostasis : Jth. 3: 796-7. PMID 15842374 DOI: 10.1111/J.1538-7836.2005.01219.X |
0.726 |
|
| 2005 |
Othman M, Notley C, Lavender FL, White H, Byrne CD, Lillicrap D, O'Shaughnessy DF. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease Blood. 105: 4330-4336. PMID 15705799 DOI: 10.1182/Blood-2002-09-2942 |
0.378 |
|
| 2005 |
Hough C, Cuthbert CD, Notley C, Brown C, Hegadorn C, Berber E, Lillicrap D. Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor. Blood. 105: 1531-9. PMID 15498853 DOI: 10.1182/Blood-2002-10-3093 |
0.754 |
|
| 2005 |
Hebbel RP, Milbauer L, Roney M, Lillicrap D, Voorberg J, Nichols TC. Use of Engineered Autologous BOEC for Gene Therapy of Canine Hemophilia A. Blood. 106: 1281-1281. DOI: 10.1182/Blood.V106.11.1281.1281 |
0.325 |
|
| 2005 |
Othman M, Labelle A, Lillicrap D. 410. Adenovirus Activates Mouse Platelets and Induces Platelet Leucocyte Association Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.413 |
0.302 |
|
| 2004 |
Rawle FE, Shi CX, Brown B, McKinven A, Tinlin S, Graham FL, Hough C, Lillicrap D. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains. The Journal of Gene Medicine. 6: 1358-68. PMID 15493040 DOI: 10.1002/Jgm.624 |
0.331 |
|
| 2004 |
Favaloro EJ, Lillicrap D, Lazzari MA, Cattaneo M, Mazurier C, Woods A, Meschengieser S, Blanco A, Kempfer AC, Hubbard A, Chang A. von Willebrand disease: laboratory aspects of diagnosis and treatment Haemophilia. 10: 164-168. PMID 15479392 DOI: 10.1111/J.1365-2516.2004.00979.X |
0.316 |
|
| 2004 |
Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. Journal of Molecular Modeling. 10: 259-70. PMID 15322948 DOI: 10.1007/S00894-004-0194-9 |
0.75 |
|
| 2004 |
James PD, O'Brien LA, Hegadorn CA, Notley CR, Sinclair GD, Hough C, Poon MC, Lillicrap D. A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons. Blood. 104: 2739-45. PMID 15226181 DOI: 10.1182/Blood-2003-12-4286 |
0.766 |
|
| 2004 |
O'Brien LA, Sutherland JJ, Hegadorn C, Benford K, Racz H, Rapson D, Hough C, Lillicrap D. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers. Journal of Thrombosis and Haemostasis : Jth. 2: 1135-42. PMID 15219197 DOI: 10.1111/J.1538-7836.2004.00732.X |
0.765 |
|
| 2004 |
Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Seminars in Thrombosis and Hemostasis. 30: 205-13. PMID 15118932 DOI: 10.1055/S-2004-825634 |
0.314 |
|
| 2004 |
Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. Haemophilia : the Official Journal of the World Federation of Hemophilia. 10: 118-33. PMID 14962201 DOI: 10.1046/J.1365-2516.2003.00853.X |
0.309 |
|
| 2004 |
Brown BD, Shi CX, Rawle FEM, Tinlin S, Mckinven A, Hough C, Graham FL, Lillicrap D. Factors influencing therapeutic efficacy and the host immune response to helper‐dependent adenoviral gene therapy in hemophilia A mice Journal of Thrombosis and Haemostasis. 2: 111-118. PMID 14717974 DOI: 10.1111/J.1538-7836.2004.00552.X |
0.341 |
|
| 2004 |
Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood. 103: 804-10. PMID 14512318 DOI: 10.1182/Blood-2003-05-1426 |
0.357 |
|
| 2004 |
Barnes C, Lillicrap D, Blanchette V, Stain AM, Pazmino-Canizares J, Clark D, Hensmen C, Carcao M. Novel and Clinically Significant Factors Influencing the Pharmacokinetic Variability of Recombinant Factor VIII (Kogenate-FS) in Children. Blood. 104: 3991-3991. DOI: 10.1182/Blood.V104.11.3991.3991 |
0.307 |
|
| 2004 |
Rand ML, Hedlund-Treutiger I, Hough C, Blanchette VS, Lillicrap D. Influence of the Variable Number of Tandem Repeat and Kozak Sequence Polymorphisms in Platelet GPIbα and the C807t α2 Integrin Polymorphism in Type 1 von Willebrand Disease. Blood. 104: 255-255. DOI: 10.1182/Blood.V104.11.255.255 |
0.311 |
|
| 2004 |
Berber E, James P, Masaru S, Leggo J, O’BRIEN L, Hough C, Lillicrap D. Detailed Biosynthethic Analysis of the Y1584C and R924Q Von Willebrand Factor Variants. Blood. 104: 1945-1945. DOI: 10.1182/Blood.V104.11.1945.1945 |
0.368 |
|
| 2004 |
Lillicrap D. Hemophilia gene therapy: it's a matter of expression Blood. 103: 5-6. DOI: 10.1182/Blood-2003-10-3531 |
0.312 |
|
| 2003 |
Scallan CD, Lillicrap D, Jiang H, Qian X, Patarroyo-White SL, Parker AE, Liu T, Vargas J, Nagy D, Powell SK, Wright JF, Turner PV, Tinlin SJ, Webster SE, McClelland A, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood. 102: 2031-7. PMID 12738670 DOI: 10.1182/Blood-2003-01-0292 |
0.366 |
|
| 2003 |
O'Brien LA, James PD, Othman M, Berber E, Cameron C, Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, Lillicrap D. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood. 102: 549-57. PMID 12649144 DOI: 10.1182/Blood-2002-12-3693 |
0.763 |
|
| 2003 |
Chuah MKL, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia a following gene therapy with high-capacity adenoviral vectors Blood. 101: 1734-1743. PMID 12406898 DOI: 10.1182/Blood-2002-03-0823 |
0.32 |
|
| 2002 |
Notley C, Killoran A, Cameron C, Wynd K, Hough C, Lillicrap D. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Human Gene Therapy. 13: 1583-93. PMID 12228013 DOI: 10.1089/10430340260201671 |
0.349 |
|
| 2002 |
Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thrombosis and Haemostasis. 88: 362-4. PMID 12195715 DOI: 10.1055/S-0037-1613214 |
0.315 |
|
| 2002 |
Hough C, Kamisue S, Cameron C, Notley C, Tinlin S, Giles A, Lillicrap D. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thrombosis and Haemostasis. 87: 659-65. PMID 12008949 DOI: 10.1055/S-0037-1613063 |
0.362 |
|
| 2002 |
Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thrombosis and Haemostasis. 87: 431-5. PMID 11916075 DOI: 10.1055/S-0037-1613022 |
0.314 |
|
| 2002 |
ORI J, TANAKA I, KUBOTA Y, MATSUMOTO T, KAMISUE S, SHIBATA M, SHIMA M, LILLICRAP D, YOSHIOKA A. The Assessment of Carrier Status of Canine Hemophilia A in a Hemophilic Colony. Japanese Journal of Thrombosis and Hemostasis. 13: 252-258. DOI: 10.2491/Jjsth.13.252 |
0.305 |
|
| 2001 |
Bitondo RD, Cameron CL, Daly ME, Croft SA, Steeds RP, Channer KS, Samani NJ, Lillicrap D, Winship PR. The −1185 A/G and −1051 G/A dimorphisms in the von Willebrand factor gene promoter and risk of myocardial infarction British Journal of Haematology. 115: 701-706. PMID 11736957 DOI: 10.1046/J.1365-2141.2001.03176.X |
0.305 |
|
| 2001 |
Lillicrap D. The genetics of venous and arterial thromboembolism. Current Atherosclerosis Reports. 3: 209-215. PMID 11286642 DOI: 10.1007/S11883-001-0063-2 |
0.321 |
|
| 2001 |
Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C, Hough C, Notley C, Lillicrap D, Kaleko M, Connelly S. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood. 97: 107-13. PMID 11133749 DOI: 10.1182/Blood.V97.1.107 |
0.333 |
|
| 2000 |
Harvey PJ, Keightley AM, Lam YM, Cameron C, Lillicrap D. A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels. British Journal of Haematology. 109: 349-53. PMID 10848823 DOI: 10.1046/J.1365-2141.2000.02000.X |
0.779 |
|
| 2000 |
Dean JA, Blanchette VS, Carcao MD, Stain AM, Sparling CR, Siekmann J, Turecek PL, Lillicrap D, Rand ML. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thrombosis and Haemostasis. 84: 401-409. DOI: 10.1055/S-0037-1614035 |
0.321 |
|
| 2000 |
Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D. The Factor VIII acute phase response requires the participation of NFκB and C/EBP Thrombosis and Haemostasis. 84: 216-222. DOI: 10.1055/S-0037-1613999 |
0.78 |
|
| 2000 |
Lee DH, Walker IR, Teitel J, Poon M-, Ritchie B, Akabutu J, Sinclair GD, Pai M, Wu JWY, Reddy S, Carter C, Growe G, Lillicrap D, Lam M, Blajchman MA. Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A Thrombosis and Haemostasis. 83: 387-391. DOI: 10.1055/S-0037-1613824 |
0.368 |
|
| 1999 |
Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notley C, Hough C, Lillicrap D, Kaleko M, Connelly S. In Vivo Evaluation of an Adenoviral Vector Encoding Canine Factor VIII: High-Level, Sustained Expression in Hemophiliac Mice Human Gene Therapy. 10: 1791-1802. PMID 10446919 DOI: 10.1089/10430349950017473 |
0.339 |
|
| 1999 |
Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 93: 4277-83. PMID 10361125 DOI: 10.1182/Blood.V93.12.4277.412K03_4277_4283 |
0.782 |
|
| 1999 |
Begbie M, Mueller C, Lillicrap D. Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes. Dna and Cell Biology. 18: 165-173. PMID 10073576 DOI: 10.1089/104454999315556 |
0.787 |
|
| 1998 |
Lillicrap D. The molecular basis of haemophilia B Haemophilia. 4: 350-357. PMID 9873754 DOI: 10.1046/J.1365-2516.1998.440350.X |
0.311 |
|
| 1998 |
Brady JN, Notley C, Cameron C, Lillicrap D. Androgen effects on factor IX expression: in‐vitro and in‐vivo studies in mice British Journal of Haematology. 101: 273-279. PMID 9609522 DOI: 10.1046/J.1365-2141.1998.00694.X |
0.382 |
|
| 1998 |
Cameron C, Notley C, Hoyle S, McGlynn L, Hough C, Kamisue S, Giles A, Lillicrap D. The Canine Factor VIII cDNA and 5’ Flanking Sequence Thrombosis and Haemostasis. 79: 317-322. DOI: 10.1055/S-0037-1614984 |
0.392 |
|
| 1996 |
McGlynn LK, Mueller CR, Begbie M, Notley CR, Lillicrap D. Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene. Molecular and Cellular Biology. 16: 1936-45. PMID 8628260 DOI: 10.1128/Mcb.16.5.1936 |
0.78 |
|
| 1996 |
Boccia LM, Lillicrap D, Newcombe K, Mueller CR. Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation. Molecular and Cellular Biology. 16: 1929-35. PMID 8628259 DOI: 10.1128/Mcb.16.5.1929 |
0.381 |
|
| 1995 |
Wood N, Standen GR, Murray EW, Lillicrap D, Holmberg L, Peake IR, Bidwell J. Rapid genotype analysis in type 2B von Willebrand's disease using a universal heteroduplex generator British Journal of Haematology. 89: 152-156. PMID 7833255 DOI: 10.1111/J.1365-2141.1995.Tb08922.X |
0.365 |
|
| 1994 |
Picketts D, Mueller C, Lillicrap D. Transcriptional control of the factor IX gene: analysis of five cis- acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations Blood. 84: 2992-3000. DOI: 10.1182/Blood.V84.9.2992.2992 |
0.39 |
|
| 1994 |
Windsor S, Taylor S, Lillicrap D. Direct detection of a common inversion mutation in the genetic diagnosis of severe hemophilia A [see comments] Blood. 84: 2202-2205. DOI: 10.1182/Blood.V84.7.2202.Bloodjournal8472202 |
0.37 |
|
| 1992 |
Picketts DJ, D'Souza C, Bridge PJ, Lillicrap D. An A to T transversion at position -5 of the factor IX promoter results in hemophilia B. Genomics. 12: 161-163. PMID 1733855 DOI: 10.1016/0888-7543(92)90421-N |
0.381 |
|
| 1991 |
Lillicrap D, Murray EW, Benford K, Blanchette VS, Rivard GE, Wensley R, Giles AR. Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease. British Journal of Haematology. 79: 612-617. PMID 1772783 DOI: 10.1111/J.1365-2141.1991.Tb08089.X |
0.391 |
|
| 1991 |
Kenwrick S, Bridge P, Lillicrap D, Lehesjoki AE, Bainton J, Gitschier J. A Taql polymorphism adjacent to the factor VIII gene (F8C) Nucleic Acids Research. 19: 2513. PMID 1675002 DOI: 10.1093/Nar/19.9.2513-A |
0.343 |
|
| 1991 |
Murray E, Giles A, Bridge P, Peake I, Lillicrap D. Cosegregation of von Willebrand factor gene polymorphisms and possible germinal mosaicism in type IIB von Willebrand disease. Blood. 77: 1476-1483. DOI: 10.1182/Blood.V77.7.1476.1476 |
0.39 |
|
| 1990 |
Bottema CDK, Koeberl DD, Ketterling RP, Bowie EJW, Taylor SAM, Lillicrap D, Shapiro A, Gilchrist G, Sommer SS. A past mutation at Isoleucine397 is now a common cause of moderate/mild haemophilia B British Journal of Haematology. 75: 212-216. PMID 2372508 DOI: 10.1111/J.1365-2141.1990.Tb02651.X |
0.359 |
|
| Show low-probability matches. |